Regulatory Requirements for Small-Scale Preparation of Radiopharmaceuticals

INTRODUCTION. The concept of pharmacy preparation of radiopharmaceuticals (RPs) was first introduced in Russia with the entry into force of the Federal Law No. 61-FZ “On Circulation of Medicines” of 12 April 2010. Recently, significant legislative changes have been gained regarding RP production and preparation. Today it has become possible to make unregistered RPs at a medical organisation covering the in-house needs, which will allow to promptly advance new methods and means to treat malignant neoplasms as well as some other diseases.

AIM. This study aimed to analyse main growth vectors for Russian organisations planning to preparing RPs.

DISCUSSION. The term “nuclear pharmacy” is applied to a special unit of a medical organisation where RFLP synthesis and quality control is carried out. The practice of foreign hospital nuclear pharmacies has proven their advantages in terms of ensuring the shortest route of vital drugs to patients. The article analyses the main requirements of Russian regulatory documents and recommendations on the functioning of a nuclear pharmacy, as well as the experience of the first nuclear pharmacy based on A.F. Tsyb Medical Radiological Research Center — Branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation. Regular work of the radiopharmacy allows to treat up to several hundred patients with vital but not yet registered drugs. However, nuclear pharmacies are far from being a routine practice for Russia, and

a number of issues has to be addressed to allow for a proper function of these pharmacies: creating a training system for radiopharmacists; defining the scope of preliminary studies of RPs extemporaneously produced at a pharmacy; updating radiation safety documents regulating process launch for new radionuclides at a pharmacy, and so on.

CONCLUSIONS. The world practice of hospital radiopharmacies has proven this system effective for RP commerce. Globally, approaches to RP preparation may be defined at the national or regional level. Pharmacies authorised to prepare RPs is a new type of pharmacy not previously known in the EAEU Member states. The creation of a regulatory framework for RP preparation should accommodate world practices with proven efficiency. The high-priority tasks to be addressed are training specialised personnel; revising a variety of documents on radiation safety; creating an expert panel assisting numerous issues associated with developing radiopharmacies; and obtaining funding sources for RP treatment.

1. Shaw SM, Ice RD. Nuclear pharmacy, Part I: Emergence of the specialty of nuclear pharmacy. J Nucl Med Technol. 2000;28(1):8–11. PMID: 10763775

2. Robinson RG, Rhodes BA. Editorial: Whither nuclear pharmacy? J Nucl Med. 1976;17(7):577–8. PMID: 1271103.

3. Ponto JA, Hung JC. Nuclear Pharmacy, Part II: Nuclear Pharmacy Practice Today. J Nucl Med Technol. 2000;28(2):76–81. PMID: 10824617

4. Ballinger JR. Hospital radiopharmacy in the UK. In: McCready R, Gnanasegaran G, Bomanji J, eds. A history of radionuclide studies in the UK. Springer Cham; 2016. P. 129–34. https://doi.org/10.1007/978-3-319-28624-2_17

5. Callahan RJ. The role of commercial nuclear pharmacy in the future practice of nuclear medicine. Semin Nucl Med. 1996; 26(2):85–90. https://doi.org/10.1016/s0001-2998(96)80029-8

6. Kodina GE, Kozlova MD, Krasnov NN, et al. A 68Ge/68Ga radionuclide generator for producing a physiologically acceptable 68Ga solution. Patent of the Russian Federation No. 2126271; 1998 (In Russ.). EDN: QSGILW

7. Waterhouse NN, Amor-Coarasa A, Nikolopoulou A, Babich JW. Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind — extended quality control and performance evaluation in the clinical production of [68Ga] Ga-PSMA-11. EJNMMI Radiopharm Chem. 2020;5(1):5. https://doi.org/10.1186/s41181-019-0087-y

8. Lee JY, Choi PS, Yang SD, Park JH. TiO2 decorated low-molecular chitosan a microsized adsorbent for a 68Ge/68Ga generator system. Molecules. 2021;26(11):3185. https://doi.org/10.3390/molecules26113185

9. Lepareur N. Cold kit labeling: The future of 68Ga radiopharmaceuticals? Front Med (Lausanne). 2022;9:812050. https://doi.org/10.3389/fmed.2022.812050

10. Dittrich RP, De Jesus O. Gallium Scan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK567748/

11. van Brandwijk EA, Aalbersberg EA, Hosseini AS, et al. Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz® kit and two generators. EJNMMI Radiopharm Chem. 2024;9(1):31. https://doi.org/10.1186/s41181-024-00260-4

12. Pandey MK, DeGrado TR. Cyclotron production of PET radiometals in liquid targets: Aspects and prospects. Curr Radiopharm. 2021;14(4):325–39. https://doi.org/10.2174/1874471013999200820165734

13. Tremblay S, Beaudoin JF, Bélissant Benesty O, et al. 68Ga-DOTATATE prepared from cyclotron-produced 68Ga: An integrated solution from cyclotron vault to safety assessment and diagnostic efficacy in neuroendocrine cancer patients. J Nucl Med. 2023;64(2):232–8. https://doi.org/10.2967/jnumed.121.263768

14. Wurzer A, De Rose F, Fischer S, et al. Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies. EJNMMI Radiopharm Chem. 2024;9(1):18. https://doi.org/10.1186/s41181-024-00246-2

15. Wojdowska W, Karczmarczyk U, Balog L, et al. Impact of DOTA-chelators on the antitumor activity of 177Lu-DOTA-rituximab preparations in lymphoma tumor-bearing mice. Cancer Biother Radiopharm. 2020;35(8):558–62. https://doi.org/10.1089/cbr.2019.3405

16. Roohi S, Rizvi SK, Naqvi SAR. 177Lu-DOTATATE peptide receptor radionuclide therapy: Indigenously developed freeze dried cold kit and biological response in in-vitro and in-vivo models. Dose Response. 2021;19(1):1559325821990147. https://doi.org/10.1177/1559325821990147

17. Waked A, Crabbé M, Neirinckx V, et al. Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma. EJNMMI Radiopharm Chem. 2024;9(1):52. https://doi.org/10.1186/s41181-024-00282-y

18. Ladrière T, Faudemer J, Levigoureux E, et al. Safety and therapeutic optimization of Lutetium-177 based radiopharmaceuticals. Pharmaceutics. 2023;15(4):1240. https://doi.org/10.3390/pharmaceutics15041240

19. Nelson BJB, Krol V, Bansal A, et al. Aspects and prospects of preclinical theranostic radiopharmaceutical development. Theranostics. 2024;14(17):6446–70. https://doi.org/10.7150/thno.100339

20. Hooijman EL, Radchenko V, Ling SW, et al. Implementing Ac-225 labelled radiopharmaceuticals: Practical considerations and (pre-)clinical perspectives. EJNMMI Radiopharm Chem. 2024;9(1):9. https://doi.org/10.1186/s41181-024-00239-1

21. Faivre-Chauvet A, Bourdeau C, Bourgeois M. Radiopharmaceutical good practices: Regulation between hospital and industry. Front Nucl Med. 2022;2:990330. https://doi.org/10.3389/fnume.2022.990330

22. Decristoforo A, Peñuelas I. Towards a harmonized radiopharmaceutical regulatory framework in Europe? Q J Nucl Med Mol Imaging. 2009;53(4):394–401. PMID: 19834449

23. Patt M, Decristoforo C, de Martini A, et al. The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe. Eur J Nucl Med Mol Imaging. 2023; 51(1):20–4. https://doi.org/10.1007/s00259-023-06472-1

24. Neels O, Patt M, Decristoforo C. Radionuclides: medicinal products or rather starting materials? EJNMMI Radiopharm Chem. 2019;4(1):22. https://doi.org/10.1186/s41181-019-0074-3

25. Konijnenberg M, Herrmann K, Kobe C, et al. EANM position paper on article 56 of the Council Directive 2013/59/ Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):67–72. https://doi.org/10.1007/s00259-020-05038-9

26. Position paper to facilitate patient access to radiopharmaceuticals: Considerations for a suitable pharmaceutical regulatory framework. EJNMMI Radiopharm Chem. 2024;9(1):2. https://doi.org/10.1186/s41181-023-00230-2

27. Moya E, Cerrato C, Bedoya LM, Guerra JA. Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation? EJNMMI Radiopharm Chem. 2024;9(1):64. https://doi.org/10.1186/s41181-024-00281-z

28. Kodina GE. The Institute of Biophysics — the birthplace of Russian nuclear medicine. In: Ilyin LA, Uiba VV, Samoilov AS, eds. Conference proceedings. dedicated to the 70th anniversary of the Burnazyan Scientific Research Center. Moscow; 2017. P. 96–117 (In Russ.).

29. Dorovatovskij SA, Petriev VM, Zverev AV, et al. Radiopharmaceutical composition for therapy of inflammatory joint diseases based on radionuclide 188Re and human albumin microspheres, as well as a composition and a method for production thereof. Patent of the Russian Federation No. 2126271; 2019 (In Russ.). EDN: DTFUFY

30. Kucherov VV, Petrosyan AP, Vlasova OP, et al. Clinical study’s results of the safety of the radiopharmaceutical labeled with Re-188 during intraarterial radioembolization. Radiation and Risk. 2024;33(3):18–29. https://doi.org/10.21870/0131-3878-2024-33-3-18-29

31. Krylov VV, Legkodimova NS, Kochetova TYu, et al. Radioligand therapy with 177Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy. Diagnostic Radiology and Radiotherapy. 2022;13(4):75–85 (In Russ.). https://doi.org/10.22328/2079-5343-2022-13-4-75-85

32. Kochetova T, Krylov V, Smolyarchuk M, et al. 188Re zoledronic acid in the palliative treatment of painful bone metastases. Int J Nucl Med Res. 2017;(S):92–100. https://doi.org/10.15379/2408-9788.2017.08